We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Fluidigm

Fluidigm Corporation focuses on the most pressing needs in translational and clinical research, including cancer, imm... read more Featured Products: More products

Download Mobile App




Molecular Methods Differentiate E. coli Outbreaks

By LabMedica International staff writers
Posted on 09 Dec 2015
The public health importance of Shiga toxin-producing Escherichia coli (STEC) infections, epidemiological and molecular surveillance systems are essential for early outbreak detection and in recent years, rapid advancements in the use of molecular typing methods have improved STEC surveillance and outbreak detection.

The application of these tools helps to identify disease clusters, refine outbreak case definitions, facilitate case finding, and link human cases to environmental sources. More...
In order to achieve these outcomes, molecular typing assays must possess the discriminatory power required to distinguish between related and nonrelated bacterial isolates, have high reproducibility, and be easy to perform.

A team of scientists led by those at the Alberta Provincial Laboratory for Public Health (Calgary, AB, Canada) assessed the capacity of either high-throughput polymerase chain reaction (PCR) of 49 virulence genes, core-genome single nt variants (SNVs) or k-mer clustering to discriminate between outbreak-associated and sporadic E. coli O157:H7 isolates. Three outbreaks and multiple sporadic isolates from the province of Alberta (Canada) were included in the study. Two of the outbreaks occurred concurrently in 2014 and one occurred in 2012.

The BioMark real-time PCR system (Fluidigm; South San Francisco, CA, USA) was used for real-time PCR amplification of 49 genetic markers using 48.48 dynamic arrays. Amplifications were performed using the dyes, 6-carboxyfluorescein (FAM)- and 6-carboxy-2’, 4, 4’, 5’, 7, 7’-hexachlorofluorescein succinimidyl ester (HEX)-labelled TaqMan probes. All amplification assays included both positive and negative controls. Detection of Stx genes, stx1 and stx2 was determined using a real-time multiplex PCR assay consisting of two separate reactions run on the ABI Prism 7500FAST Sequence Detection System (Life Technologies, Inc.; Burlington, ON, Canada).

Pulsed-field gel electrophoresis (PFGE) and multilocus variable-number tandem repeat analysis (MLVA) were employed as comparator typing methods. The virulence gene profiles of isolates from the 2012 and 2014 Alberta outbreak events and contemporary sporadic isolates were mostly identical; therefore the set of virulence genes chosen in the study were not discriminatory enough to distinguish between outbreak clusters. Concordant with PFGE and MLVA results, core genome single-nucleotide variations (SNV) and k-mer phylogenies clustered isolates from the 2012 and 2014 outbreaks as distinct events. The k-mer phylogenies demonstrated increased discriminatory power compared with core SNV phylogenies.

The authors concluded that whole genome sequencing (WGS) holds significant potential to replace current gold-standard typing methods such as PFGE for the routine surveillance and detection of enteric outbreaks. This shift will be driven by the advantages offered by WGS such as increased discriminatory power and genetic resolution. The study was published on November 26, 2015, in the journal Eurosurveillance.

Related Links:

Alberta Provincial Laboratory for Public Health
Fluidigm 
Life Technologies, Inc. 



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.